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Review
Peptide gene expression in gastrointestinal mucosal ulceration:
ordered sequence or redundancy?
Summary
Many genes, some encoding peptides, are upregulated after
mucosal damage in the gastrointestinal mucosa: we have
looked for an ordered sequence in the expression of genes
such as c-fos, c-jun, egr-1, Sp-1, epidermal growth factor,
transforming growth factors á and â, trefoil peptides, epi-
dermal growth factor receptor, hepatocyte growth factor,
c-met, fibroblast growth factor, platelet derived growth fac-
tor, and vascular endothelial growth factor. All of these
gene products play an important reparative role, assisting
appropriate healing of the damaged mucosa. There does
indeed seem to be a temporal sequence in this gene
expression, but there is a certain degree of redundancy
within the system, both in terms of receptor binding and
the function of the gene products. However, it is probable
that the integrated function of these genes and their prod-
ucts safeguard the important healing properties of the
gastrointestinal mucosa. Although the function of indi-
vidual gene products is of course important, it now seems
critical to explore the inter-relations between these genes
and their encoded products to explain fully mucosal regen-
eration after damage.
Introduction
The gastrointestinal tract is subjected to a wide variety of
mucosal challenges. Helicobacter pylori associated ulcer dis-
ease, non-steroidal anti-inflammatory drug (NSAID) asso-
ciated ulcers, alcohol induced mucosal injury, and a variety
of inflammatory conditions, including ulcerative colitis and
Crohn’s disease. No matter what the cause of the
ulceration, the mucosa usually responds rapidly by trigger-
ing oV a cascade of repair mechanisms to stimulate repair
and restore mucosal integrity. Many genes are induced by
the damage: apart from early response genes such as c-fos,
c-jun, egr-1, and Sp-1, genes encoding peptides are
particularly well represented; there is increasing evidence
that at least 30 such genes are involved in the process. In
the main, most investigators have pursued the time
honoured reductionist approach, singling out individual
peptides for detailed attention. However, these peptides are
not all expressed at the same time, but follow an apparently
ordered sequence. One point which does not seem to have
been at all tackled in this field is that many of these peptides
have similar actions, prompting the reasonable
question—is gene expression after mucosal damage largely
redundant, or is there an ordered sequence, with intrinsic
interdependency? In this article, we will examine the
importance of these peptides in the ulcer healing process,
and attempt to identify the sequential gene expression of
these peptides after ulceration.
The main players
Trefoil factors (TFF) derive their name from their cysteine
rich “three leafed” structure.1 2 TFFs are produced rapidly
at sites of injury and stimulate the repair process. Three
members of this family are present in human gastro-
intestinal mucosa: TFF1/pS2, TFF2/SP, and TFF3/ITF.
The production of all three trefoil peptides is upregulated
at sites of mucosal injury, and they participate in mucosal
repair by stimulating the migration of surviving cells from
the edge of the damaged region over the denuded area, a
process known as epithelial restitution. Exogenous
TFF2/SP increases cell migration in in vitro models of cell
wounding3 4 and also acts as a cytoprotective agent in rats
treated with indomethacin. Thus TFF2/SP has been
proposed as a rapid response peptide.5
Epidermal growth factor (EGF) is an 53 amino acid
peptide found in the salivary glands and the duodenal
Brunner’s glands. It is one of the most extensively studied
peptides in healing of gastric mucosal lesions,6–9 but its
exact function in human physiology is not yet fully defined.
EGF is a potent stimulant of growth and repair when
infused systemically, inhibits gastric acid secretion, and has
a cytoprotective eVect on the gastrointestinal mucosa. It is
also one of the main peptides secreted by repair lineages of
the gastrointestinal tract—for example, the ulcer associated
cell lineage.10 The EGF receptor (EGFR) is a single pass
transmembrane protein of about 1200 amino acid residues
and has a glycosylated extracellular domain that binds
EGF, leading to the activation of an intracellular tyrosine
kinase domain which causes the phosphorylation of cellu-
lar proteins. Apart from EGF, several other ligands also
bind to EGFR, such as transforming growth factor (TGF)
á, amphiregulin, heparin-binding EGF-like growth factors,
and betacellulin. Interestingly, in many studies luminal
EGF has very little eVect on growth or acid secretion of the
non-damaged gastrointestinal mucosa. The reason for this
discrepancy may be that the EGFR on gut epithelial cells is
restricted to the basolateral surface and is not present on
the apical luminal surface in rat or human.11 12 Luminal
EGF is therefore only able to bind to its receptors when the
bowel has been damaged, and thus might be best
considered as a luminal surveillance peptide—constantly
available but possessing little function unless damage has
occurred.5 The proposal that EGF acts in a surveillance
role is supported by the finding that removal of the
submandibular glands from rats does not cause spontane-
ous ulcer development, but does reduce the rate of healing
if an ulcerogen is co-administered.13
Transforming growth factor á is synthesised as a 160
amino acid precursor molecule that spans the cell
membrane. Subsequent exposure of the external domains
to specific proteases releases a 50 amino acid residue pep-
tide that shares 35% homology with epidermal growth fac-
tor. TGF-á is expressed throughout the gastrointestinal
tract in rats and humans14 15 and although the biological
function of the membrane bound form is unclear, it may
function in a juxtacrine manner on adjacent cells. TGF-á is
normally trophic to a variety of cell lines in vitro and to the
intestine of rats when given systemically.16 Furthermore,
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the administration of TGF-á decreases the extent of gastric
damage when rats are exposed to ulcerogens such as etha-
nol or stress.17 It has been shown that TGF-á mRNA
increases in a dose and time dependent manner in the gas-
tric mucosa of rats after administration of taurocholate.18 In
addition, there was a 68-fold increase in immunoreactive
TGF-á in gastric juice within 30 minutes of gastric instil-
lation of hydrochloric acid. The origin of this rapid increase
in TGF-á after gastric mucosal injury remains speculative:
it may be caused by proteolysis of the transmembrane form
or lysis of injured gastric mucosal cells. Recruitment of
inflammatory cells into the injured area may also result in
increased concentrations of TGF-á, but the paucity of
inflammatory cells observed in histological sections taken
early after the injury, and the low concentration of TGF-á
in the serum, indicates that the TGF-á most likely
originates from the gastric mucosa.18
These studies support the idea that the predominant role
of TGF-á is to maintain normal epithelial integrity, acting
predominantly by direct epithelial eVects. Thus it may be
regarded as a mucosal integrity peptide.5 Another example
of such a mucosal integrity peptide is pancreatic secretory
trypsin inhibitor (PSTI) which is secreted into the mucus
layer to prevent excessive digestion by refluxed pancreatic
proteases and to decrease the rate of mucus digestion by
luminal proteases within the stomach and colon.19 PSTI is
found in mucus secreting cells throughout the gastro-
intestinal tract and also in the kidney, lung and breast, and
both increases the proliferation of a variety of cell lines and
stimulates cell migration, possibly acting via the EGFR.
Thus PSTI may also be involved in both the early and late
phases of the healing response following injury.20
Hepatocyte growth factor (HGF) is secreted from stro-
mal fibroblasts as a single chain, biologically inactive
precursor (pro-HGF) and converted to an active het-
erodimeric protein by a novel serine protease (HGF
activator).21 22 This proteolytic process is probably essential
for HGF to exert its mitogenic activity.23–25 Critically, HGF
is only converted to its active heterodimeric form in injured
tissue, suggesting that selective activation of HGF by HGF
activator is a mechanism by which HGF action is localised
to damaged tissues.25 HGF binds to the c-met receptor
(HGF receptor) to exert its action and the concentration of
c-met receptor is increased in the gastric mucosa after
injury.26 Thus active HGF, when produced in the stomach
after injury, may stimulate the proliferation of gastric
mucosal epithelial cells through increased HGF receptor
concentrations. Accompanying increased expression of the
HGF gene, increased interleukin (IL) 1á mRNA expres-
sion was found in the ulcerated gastric wall. IL-1á may act
as the link between the ulcerated tissue and submucosal
production of HGF in the indomethacin induced gastric
injury model.27 HGF is also linked to the presence of H
pylori and abnormal mucosal growth in patients with large-
fold gastritis28: eradication of H pylori results in a reduction
in fold thickness and a parallel fall in HGF concentrations,
suggesting that HGF is important in this trophic response.
Moreover, a molecular link between H pylori, HGF and
abnormal mucosal growth may be mediated by the
cytokine IL-1â, as administration of an IL-1â antagonist
reduces the production of HGF.28 Thus this experimental
model may provide some insight into the link between the
presence of H pylori, cytokine and growth factor produc-
tion and abnormal mucosal growth, possibly illuminating
the relation between H pylori and gastric carcinogenesis.
Transforming growth factor â is another peptide
involved in mucosal defence, but in contrast to other
growth factors, its function is to turn oV the proliferation of
epithelial cells once they have left the crypts or glands. It is
also a potent stimulant of cell migration. Interestingly, the
stimulation of cell migration by TGF-á and EGF, but not
trefoil peptides, is dependent on the release of TGF-â.3 4 29
Basic fibroblast growth factor (bFGF) is normally
present in the human gastric mucosa, and is a potent
stimulant of angiogenesis, accelerating healing of experi-
mental gastric and duodenal ulcers in rats.30 31 Administra-
tion of recombinant bFGF in patients with NSAID associ-
ated gastric ulcers is associated with a reduction in ulcer
incidence, with a healing rate of 44% at one month and a
mean reduction of 90% in the area of the unhealed ulcer.32
In ulcerated human gastric mucosa, immunoreactive
bFGF is upregulated in the granulation tissue, endothelial
cells, mononuclear cells, and epithelial cells at the ulcer
rim.33 However, no increased bFGF mRNA is detectable
by in situ hybridisation, suggesting that bFGF mRNA
expression may be an early event after mucosal injury, as
has been reported in rats.34
Platelet derived growth factor (PDGF) was first
detected, as its name suggests, in platelets, but it is also
synthesised and secreted by activated macrophages. PDGF
consists of two disulphide linked polypeptides: chain A (14
kDa) and chain B (17 kDa).35 Three isoforms exist:
PDGF-AA, -AB, and -BB. PDGF is a potent mitogen for
fibroblasts, osteoblasts, arterial smooth muscle cells, and
glial cells.36 37 Both bFGF and PDGF accelerate the healing
of cysteamine induced duodenal ulcers in rats by stimulat-
ing angiogenesis and granulation tissue formation, and are
two million times more potent than cimetidine.38 More-
over, after experimentally induced duodenal ulcer and
colitis in rats, both the duodenal and the colonic
concentrations of bFGF and PDGF were reduced, but
then increased in the healing phases of both lesions. Thus
sequential expression of healing peptides occurs in the
foregut and the hindgut.39
Vascular endothelial growth factor (VEGF) is a peptide
synthesised by vascular endothelial cells.40 Alternate exon
splicing of a single VEGF gene results in four molecular
species: 121, 165, 189, and 206 amino acid residues. The
121 and 165 splice variants constitute the secretory form of
VEGF, whereas the others are mainly cell associated.
VEGF plays a dual role in acute gastroprotection and
chronic duodenal ulcer healing.41 The increased vascular
permeability produced by VEGF seems to protect the gas-
tric mucosa by the formation of a perivascular dilutional
barrier towards gastrotoxic chemicals. VEGF then stimu-
lates granulation tissue formation and angiogenesis to pro-
mote ulcer healing. It has been shown that upregulation of
VEGF mRNA expression occurs as early as three hours
after ethanol induced gastric mucosal injury.42
Patterns of peptide gene expression after mucosal
injury
Many genes are upregulated after gastric mucosal injury
but are not expressed at the same time. Some genes are
initially expressed early, and might be called early response
genes, such as EGFR, c-fos, c-jun egr-1, Sp-1, and
TFF2/hSP, whereas EGF, TGF-á, bFGF, PDGF, and
VEGF appear some time later and might be referred to as
intermediate genes. HGF and TFF3/ITF are usually
expressed late in the process of ulcer healing (fig 1) and in
their turn might be termed late genes.
The transcription factors c-fos, c-jun, c-myc, egr-1, and
Sp-1 are activated during the process of ulcer healing and
are usually called immediate early genes because their
rapid and transient transcriptional induction does not
require de novo protein synthesis.43 44 The fos and jun fam-
ily proteins are transcription factors which form het-
erodimers (fos–jun) or homodimers (jun–jun), potent tran-
scription factors which bind to the activator protein-1 site
of various target genes, and contribute to the cellular
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response to primary stimuli: c-fos and c-myc are thus impli-
cated in the control of cell proliferation in a variety of cell
types. The expression of c-myc and c-Ha-ras genes is
increased after indomethacin induced mucosal injury of
the rat stomach,45 with c-myc localised to nuclei as early as
three hours after injury, whereas c-Ha-ras is localised to the
cytoplasm, peaking at six to 12 hours after treatment.
Changes in the expression of c-fos and c-myc in stress
induced ulcers shows that c-fos mRNA is found in the gas-
tric mucosa as early as two hours and c-myc mRNA at six
hours after damage.46 The change in the expression of
c-myc and c-fos precedes the induction of DNA synthesis as
measured by [3H] thymidine incorporation. Stress induced
ornithine decarboxylase (ODC) activity in the gastric
mucosa increases mucosal polyamines such as putrescine,
spermidine, and spermine.46 Administration of á-difluoro-
methylornithine (DFMO), a specific inhibitor of ODC,
prevented the notable increase in ODC activity and
polyamine concentrations, whereas the expression of c-fos
was completely abolished and c-myc mRNA was greatly
decreased. Thus c-fos and c-myc are involved in the mech-
anism of polyamine stimulated healing in gastric mucosal
stress ulcers.
In the cysteamine induced duodenal ulcer model in the
rat, egr-1 mRNA is expressed as early as 30 minutes after
administration. Similarly, Sp-1 expression shifted from the
lower to higher molecular weight form at two hours after
cysteamine exposure.47 Both egr-1 and Sp-1 expression
precedes the increase in bFGF mRNA at 12–24 hours.
Clues on specific transcriptional regulators come from a
knowledge of the promoter sequence of bFGF, where
GC-rich elements play a role in bFGF expression: the
ubiquitous transcription factor Sp-1 recognises many of
these GC-rich regions, suggesting that it might play a role
in the regulation of bFGF gene transcription. Both Sp-1
and egr-1 seem to be important in the healing of duodenal
ulceration, particularly in regulating bFGF and possibly
PDGF expression after duodenal ulceration. These data
suggest that immediate early genes may start the healing
cascade in gastric mucosal lesions.
Most data concerning gene expression after mucosal
injury come from animal models of ulceration. Alison et al
used the cryoprobe to induce ulcers in rodent stomach and
examined the sequential expression of rTFF2/rSP, rTFF3/
rITF, EGF, and TGF-á.48 Ribonuclease protection assays
on the gastric tissue after cryoprobe treatment showed
increased rTFF2/rSP mRNA expression very early in the
healing process (fig 2). Peak induction occurred between
30 minutes and two hours after damage, but declined
thereafter to reach control values after 12 hours of
cryoprobe treatment. Thirty minutes after ulcer induction,
immunoreactive TFF2/SP was located both in the mucous
neck cells of the gastric glands, where it is usually found,
and also within the lamina propria and between underlying
muscle fibres, suggesting that rTFF2/SP had been released
from the mucous neck cells or other storage sites, following
tissue injury. In contrast, rTFF3/ITF mRNA was first
detected on day 2, peaking at three days after ulcer induc-
tion and remained increased at least 10 days after the
injury. EGF mRNA was detected after one day, peaking at
three days and remained greatly increased at 10 days after
cryoprobe application, whereas TGF-á mRNA expression
increased greatly only six days after the injury (fig 2).
Interestingly, in an model of 100% glacial acetic induced
gastric injury in mice, the concentrations of mTFF2/SP
and mTFF3/ITF fell in gastric tissue within 48 hours of
ulceration but the concentrations of mTFF2/SP and
mTFF3/ITF increased at 42 days and 72 days after injury,
suggesting that they may have an ongoing role in the repair
process. This late induction of TFF2/SP and TFF3/ITF
has a TGF-á dependent component.49
A similar time sequence study in experimental ulceration
showed that the expression of EGF and TGF-á mRNA
precedes the expression of immunoreactive EGF and
TGF-á: the expression of EGF and TGF-á mRNA
occurred at days 2 and 4 at the ulcer margin, whereas
immunohistochemical EGF and TGF-á over-expression
occurred at day 4 after ulcer induction.50 The expression of
EGF and TGF-á was also correlated with the PCNA
labelling index, emphasising the importance of these
growth factors as mediators of cell proliferation during
ulcer healing. Interestingly, gastric acid secretion was sup-
pressed during ulcer healing, and was accompanied by
increased plasma gastrin concentrations. The increase in
plasma gastrin concentrations could be secondary to a
reduction in gastric acid secretion, which may be mediated
by EGF and TGF-á,51 52 but alternatively, the presence of
an EGF response element in the gastrin promoter might
explain the stimulation of gastrin gene transcription by this
peptide.53
There is also over-expression of EGFR in rat gastric
mucosa during healing of acetic acid induced ulcers.54 The
EGFR possesses intrinsic tyrosine kinase activity in the
intracellular domain, and the tyrosine kinase activity asso-
ciated with EGFR was greatly (more than 200%) increased
within 30 minutes after gastric mucosal injury, suggesting
that activation of this enzyme may be an important early
event in the initiation of the reparative process.55 Moreover,
24 hours after gastric mucosal injury produced by
hypertonic saline, EGFR concentrations were increased
36-fold, which closely correlated with mucosal
regeneration56; the expression of EGFR mRNA rose
gradually throughout the reparative period to 80% above
the controls at four hours after 2 M NaCl induced injury.57
These studies clearly show that the activation of EGFR is
an important early event in gastric mucosal regeneration
following acute injury.
Hepatocyte growth factor, one of the heparin binding
growth factors, is one of the most potent mitogens for gas-
tric cells in vitro,58 59 as well as acting as a morphogen.60–63
HGF gene expression is augmented at five days after the
induction of ulcers by acetic acid, reaching maximal levels
on the tenth day.28 64 In situ hybridisation with 35S-labelled
rat HGF cRNA probes showed that expression of HGF
mRNA occurs in the submucosal layer around the ulcer
lesions, with no HGF mRNA expression in the non-ulcer
regions. Expression of c-met mRNA, the receptor for HGF,
was increased six to 48 hours after mucosal injury induced
by administration of hydrochloric acid.26 Furthermore, in a
Figure 1 Temporal expression of genes in experimental models of
ulceration in the rat. The time scale shown on the x-axis is expressed in
days after mucosal injury. bFGF, basic fibroblast growth factor; EGF,
epidermal growth factor; HGF, hepatocyte growth factor; IEG, immediate
early genes; PDGF, platelet derived growth factor; TGF, transforming
growth factor; TFF, trefoil factors; VEGF, vascular endothelial growth
factor.
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model of cryoprobe induced gastric ulcer in rats, in situ
hybridisation showed that mRNA of both HGF and c-met
is strongly expressed after cryosurgery in the early (day 3)
as well as in the late (day 15) remodelling phase of ulcer
healing.65 HGF mRNA is located in stromal cells between
the regenerative glands and in the arterial vessels in the
submucosa, whereas c-met mRNA is located in the epithe-
lial cells of the regenerative glands.
The expression of bFGF and its receptor (FGFR-1 and
FGFR-2) in alcohol induced gastric ulcers in rats showed
a great increase in bFGF mRNA at eight and 24 hours after
injury,34 followed by an increase in bFGF protein,
beginning at 24 hours and lasting until 72 hours after
injury. Similar increases in FGFR-1 and FGFR-2 mRNAs
and proteins were also detected, and thus gastric mucosal
injury results in a temporally restricted increase in bFGF
and FGFR-1 and -2 mRNAs and proteins.
Keratinocyte growth factor (KGF), a member of the
fibroblast growth factor family (FGF7) is a potent
stimulant of keratinocyte proliferation27 and binds to a
splice variant of FGFR-2. It has been shown to ameliorate
damage in an experimental model of colitis in rats.67 But
KGF mRNA expression was not increased after indometh-
acin or acetic acid induced gastric injury in rats,27 and it is
ineVective at reducing indomethacin induced gastric
damage.68 Current data are insuYcient to judge whether
KGF plays an important role in gastric ulcer healing.
An ordered gene cascade or genetic redundancy
after gastric mucosal damage?
It is clear that a wide variety of genes which encode peptides
are expressed or upregulated, or both, after gastric mucosal
injury. c-jun, c-fos, egr-1, and Sp-1 are activated early in the
process, acting as transcription factors, molecular switches
triggering the expression of other target genes, but details of
the target genes activated by these transcription factors are
not known as yet, and further studies are required. A tempo-
ral relation may exist between the expression of diVerent
peptides: some early response peptides such as TFF2 /SP are
involved in epithelial restitution which indeed does occur
within the first few hours, covering the denuded area, and is
not dependent on cell division. Later, the classic healing
peptides such as EGF and TGF-á join in to stimulate
growth and repair, and TFF3/ITF, another motogen, is also
ectopically expressed in the stomach later in the response.
HGF, bFGF, KGF, PDGF, and VEGF are produced from
cells of mesodermal origin, and assist in the healing and
repair process by stimulating proliferation and diVerentia-
tion of epithelial cells. Importantly, gene products such as
bFGF, PDGF, and VEGF can also stimulate angiogenesis,
which may improve the quality of healing.69 It seems that
each set of genes has a particular role in the healing process
and they are expressed in an ordered manner to act in an
integrated fashion to ensure appropriate healing of the
injured mucosa.
There is, however, apparent redundancy in the expres-
sion of genes and peptides involved in mucosal repair. For
example, there is a considerable degree of redundancy in
the EGF family, which permits substitution should one
gene be missing or have been knocked out. In the EFGR
knockout mouse, the animals can still survive, albeit briefly,
for about a week after birth, but they then succumb to res-
piratory distress or to a necrotising enterocolitis-like
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Figure 2 Changes in the level of
mRNA after cryoprobe application in
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region in rats. â-actin concentrations (A)
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syndrome.70 When the TGF-á gene is knocked out, the
healing of acetic acid induced gastric ulcers is the same in
knockout and wild-type mice, but the expression of
TFF2/SP and TFF3/ITF is suppressed in the TGF-á
knockout mice in the later stage of gastric mucosal
rebuilding.49
Similar redundancy is noticed when we examine the
function of these peptides. For example, EGF, TGF-á, and
HGF are all powerful mitogens, but they seem to act in a
diVerent time frame in the healing process. Moreover, EGF
and TGF-á are both secreted by epithelial cells but HGF is
secreted by mesenchymal cells. The spatial and temporal
expression of peptides by diVerent cells in the damaged
mucosa might ensure an appropriate supply of these heal-
ing peptides. Similarly, TGF-â, EGF, TGF-á, TFF
peptides, and HGF are motogens, involved in epithelial
restitution. But EGF and TGF-á act though a TGF-â
dependent pathway3 4 71 at the basolateral (serosal) side of
the gastrointestinal epithelium whereas TFF peptides are
luminally active and are also TGF-â independent.3 4
This redundancy within the system may thus allow
diVerent genes or peptides to replace the function of
others, possibly in the face of loss of function of other gene
products with the same actions. The repertoire of peptides
and genes may safeguard the important healing and repair
properties of the gastrointestinal mucosa. Furthermore,
this complex system of gene interactions might allow the
mucosa to use diVerent mechanisms in diVerent circum-
stances, increasing the plasticity of the response to diVerent
environmental insults.
Inter-relations between the players
We have seen that there is some pattern in gene expression
after mucosal damage; consequently, it is again reasonable
to query the possible interactions between the main
players. Some growth factors can induce the expression of
intermediate early genes such as c-jun and c-fos in
gastrointestinal epithelial cells. For example, TGF-á
increases the rate of thymidine incorporation, the activity
of mitogen activated protein kinase, S6 kinase, and expres-
sion of c-fos, c-jun, and c-myc in the intestinal epithelial cell
line IEC-6.72 73 EGF also stimulates the proliferation of
cells derived from the gastric fundus and induces the
expression of c-fos and c-myc.74 Although the TGF-á and
EGF genes are upregulated only late in the response to
damage, we should note that upregulation of EGFR occurs
quite early,54 and it is possible that the loss of cells from the
surface allows luminal EGF to bind its basolateral receptor
on surviving adjacent epithelial cells and induce these early
genes.
Besides interaction with the immediate early genes,
many of the peptides involved in mucosal repair might act
in an integrated fashion. For example, expression of
TFF1/pS2 at sites of mucosal damage may be mediated by
luminal EGF as TFF1/pS2 has an EGF-responsive
enhancer region in the 5' controlling sequence.75 Thus
when ulceration occurs, luminal EGF binds its receptor on
the basolateral membranes of the epithelial cell and
induces trefoil peptide gene expression, also a result of the
early EGF:EGFR interaction. This enhancer region is also
responsive, though not so strongly, to early response gene
products such as the c-ras and c-jun. Furthermore, EGF
and trefoil peptides can act together in a synergistic man-
ner to stimulate the repair process,76 but whether this
involves a separate trefoil receptor or is mediated wholly via
the EGFR is not yet known. We have noted that EGF, a
luminal surveillance peptide, and TGF-á, a mucosal integ-
rity peptide, act on the same receptor: the diVerence in
classification relates to their ability to reach the receptor
rather than the intrinsic diVerences in the molecules them-
selves. Furthermore, a number of peptides, such as EGF,
are monomeric in solution yet have been shown to activate
their cognate receptors by inducing dimerisation. Thus
EGF may signal to the cell through the formation of recep-
tor homodimers (where two EGF or c-erb-B1 receptors
link together) or through the formation of heterodimers
(where one c-erb-B1 receptor binds to another activated
member of the c-erb-B receptor family such as c-erb-B4,
Figure 3 Diagram showing possible relations among epidermal growth factor (EGF), transforming growth factor (TGF) á, gastrin, trefoil peptides, basic
fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and immediate early genes after
gastric mucosal injury.
Mucosal injurybFGF VEGF
PDGF
EGF and TGF-
expression and production
Expression in immediate
early gene (IEG): c-fos, c-jun,
egr-1, Sp-1
Activate transcription of
target genes
Stimulate angiogenesis and
granulation tissue formation
Stimulate EGFR on
antral G cells
Trophic effect on
the damaged mucosa
Acid secretion by
parietal cells
(avoid excessive acid
secretion through the
primary action of EGF
and TGF- )
EGFR expression
Stimulate expression
of trefoils through
EGF responsive
enhancer region
Synergistic effect
with EGF
No effect
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which binds heregulin). This ability to form heterodimers
greatly increases the variety and repertoire of ligand–
receptor interactions.77
There is also evidence that EGF upregulates the expres-
sion of its own intestinal receptor (EGFR) after small
bowel resection in rats.78 Similar mechanisms may operate
in the stomach in response to injury, thus forming a posi-
tive feedback loop to augment the reparative and healing
ability of the injured mucosa.
Epidermal growth factor and TGF-á have a physiologi-
cally complementary eVects on gastric acid secretion and
mucosal growth in the stomach. Both EGF and TGF-á
directly stimulate mucosal growth and inhibit gastric acid
secretion, but EGF stimulates the transcription of gastrin,
a peptide hormone which regulates gastric acid secretion
and mucosal growth, mediated by a GC-rich gastrin
response element located at −68 to −53 bp upstream from
the cap site.53 The dependence of gastrin gene expression
on EGF (TGF-á) stimulation might represent a powerful
control mechanism in which the trophic eVect of gastrin is
switched on while at the same time avoiding excessive acid
secretion by the primary action of EGF and TGF-á (fig 3).
Conclusion
It has been clear for a long time that a large variety of genes,
cytokines, and peptides are involved in the process of ulcer
healing. The reductionist approach has been essential to
the initial understanding of the action of the individual
players, each with its particular role in the repair and
regeneration process. However, we are now in possession of
a good deal of information about each player, and have
noted a certain degree of redundancy within the system.
Consequently, it is indeed germane to begin to search for
the mechanisms which order this gene sequence, and for
further interactions. It is only when we find these that we
will fully understand the process; our meagre knowledge of
these interactions is certainly indicative of a highly
integrated response.
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